News
TS Picks — Day 7: 3 Stocks to Watch | EFOR, RELY & XERS | THINKSABIO
Oct 14, 2026 · ThinkSabio Inc
ThinkSabio TS Picks highlights three stocks showing a mix of government AI exposure, strong financial growth, and upcoming healthcare catalysts. Here’s what investors should know about today’s picks.
🔹 #EFOR — Everforth
$115M U.S. Army AI contract strengthens its AI and digital engineering business, supported by increasing government demand for AI, cloud, cybersecurity and digital engineering solutions.
Key Highlight: Continued federal AI and digital transformation contracts could provide additional growth opportunities.
👉 Detailed Analysis: View EFOR Analysis
🔹 #RELY — Remitly Global
Q2 2026 revenue increased 20% YoY to $495.2M, while adjusted EBITDA surged 79% YoY to $114.7M. Strong customer growth and higher send volumes continue to support the company’s expansion and improving profitability.
Key Highlight: Remitly is expanding beyond traditional remittances into a broader cross-border payments platform.
👉 Detailed Analysis: View RELY Analysis
🔹 #XERS — Xeris Biopharma
Recorlev revenue grew 81% YoY to approximately $57M in Q2 2026, highlighting strong commercial growth. The company also expects XP-8121 Phase 3 initiation in Q4 2026, providing an important upcoming clinical catalyst.
Key Highlight: Growing commercial revenue combined with the advancing pipeline makes XERS a stock to watch.
👉 Detailed Analysis: View XERS Analysis
📊 Why Watch These 3 Stocks?
EFOR → Government AI & digital engineering
RELY → Revenue growth & improving profitability
XERS → Commercial growth & clinical catalysts
🚀 Bottom Line
Today’s TS Picks bring together three different growth themes: AI and government technology, digital payments, and biopharma innovation. These stocks offer different catalysts and risk profiles, making them worth watching as their respective growth drivers develop.
Want more daily stock picks, market insights and detailed analysis?
👉 Join the ThinkSabio Stocks WL999 Group
🌐 ThinkSabio Community
Share this post
💬 Comments
Loading comments…
Leave a comment
